ArticleTransboundary and emerging diseases2024
SARS-CoV-2 Seroprevalence in Indoor House Cats From the Lisbon Area During the COVID-19 Pandemic, 2019-2021.
Article in Transboundary and emerging diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prevalence, Clinical Signs, Diagnosis and Treatment of Post-Pandemic SARS-CoV-2 Infection in Cats in 2023: Co-Infection with FHV, FCV,Veterinary sciences · 2026Article
- Detection of SARS-CoV-2 antibodies in companion animals in Poland during the post-pandemic period (2022-2025).BMC veterinary research · 2025Article
- Seroprevalence of SARS-CoV-2 in cats from COVID-19 positive households in the Lisbon area.Frontiers in veterinary science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The susceptibility of various animal species to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been studied extensively. Cats have garnered significant concern due to their high susceptibility and proximity to humans. This study aimed to evaluate the susceptibility and antibody response in house cats exposed to SARS-CoV-2 when human infection was spreading in the Lisbon area during the 2019-2021 period. A total of 733 serum samples were collected and characterized from cats admitted to the Veterinary Teaching Hospital of the Faculty of Veterinary Medicine at the University of Lisbon (HEV-FMV-ULisboa). All samples were tested by enzyme-linked immunosorbent assay (ELISA) for immunoglobulin M (IgM) and immunoglobulin G (IgG) anti-SARS-CoV-2 whole Spike and receptor-binding domain (RBD) proteins from the Wuhan-Hu-1 isolate and 14.7% (108/733) tested positive, suggesting exposure to the human virus. Surrogate virus neutralization test (sVNT) against the Wuhan-Hu-1 isolate showed that 20.4% of ELISA positive samples (22/108) harbored neutralizing antibodies against the virus. The 22 most promising serum samples were retested using ELISA and sVNT against Alpha, Delta, and Omicron SARS-CoV-2 variants. Notably, these samples exhibited antibodies that were capable of recognizing and neutralizing these variants. Subsequent neutralization assays confirmed that the serum samples effectively inhibited the infection process of Wuhan-Hu-1 D614G, Delta, and Omicron SARS-CoV-2 pseudotyped viruses. Our findings indicate that cats were exposed to SARS-CoV-2 infection during the pandemic period and generated highly effective and broadly neutralizing antibodies against the virus. Although cats have not been demonstrated to significantly contribute to the spread of SARS-CoV-2, their high susceptibility to asymptomatic infection underscores the importance of investment in preventive surveillance measures. In summary, our study reinforces the notion that cats naturally infected with SARS-CoV-2 represent a valuable anthroponotic disease model in house settings and might be a potential source for the development of antibodies against SARS-CoV-2 in tackling future outbreaks with a One Heath perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.